- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04703582
Relationship Between Morbimortality and Basal Activated Clotting Time (ACT) in Patients Undergoing Vascular Surgery
January 8, 2021 updated by: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Check whether patients with higher comorbidity and risk of complication, estimated using the V (p) -POSSUM score, ACS NSQIP and the ASA classification, present higher baseline activated clotting time values.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
30
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing vascular surgery consecutively in the first semester of 2021, for a period of one month, will be included.
Description
Inclusion Criteria:
- Patients undergoing vascular surgery requiring intraoperative heparinization
Exclusion Criteria:
- Pregnant women
- SARS-CoV-2 PCR positive (performed 24-72h prior to surgery)
- Severe plaquetopenia <50,000
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change on baseline Activated Clotting Time with comorbidities
Time Frame: 1 day - surgery day
|
Activted Clotting Time will be measured with Haemocron Machine just before surgery.
Comorbidities will be measured with V(p)Possum, AC NSQUIP and ASA scales.
|
1 day - surgery day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2021
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
June 1, 2021
Study Registration Dates
First Submitted
January 4, 2021
First Submitted That Met QC Criteria
January 8, 2021
First Posted (Actual)
January 11, 2021
Study Record Updates
Last Update Posted (Actual)
January 11, 2021
Last Update Submitted That Met QC Criteria
January 8, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Vascular Diseases
- Disease
- Peripheral Arterial Disease
- Carotid Artery Diseases
- Aortic Diseases
Other Study ID Numbers
- IIBSP-TCA-2020-92
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.